Clinical Trial Update: Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing pembrolizumab (MK-3475) in metastatic melanoma patients naive to immune therapy, using systems biology for tumor microenvironment analys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Centre Hospitalier Universitaire Vaudois | Conditions: Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting | Phase 2 | Status: ACTIVE_NOT_RECRUITING